ARTÍCLES Alserawan, L., Anguera, G., Zamora Atenza, C., Serra López, J., Martínez-Martínez, L., Riudavets Melià, M., Sullivan, I., Barba Joaquin, A., Majem Tarruella, M., & Vidal, S. (2024). Association between changes in the patterns of antinuclear autoantibodies during immune checkpoint inhibition therapy and the development of severe immune related adverse events. Anguera, G., Mulet, M., Zamora, C., Osuna-Gómez, R., Barba, A., Sullivan, I., Serra-López, J., Cantó, E., Vidal, S., & Majem, M. (2024). Potential role of circulating PD-L1+ leukocytes as a predictor of response to anti-PD-(L)1 therapy in NSCLC patients. Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-Small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. Mariona Riudavets, Joaquin Mosquera, Rosario Garcia-Campelo, Jorgina Serra, Georgia Anguera, Pablo Gallardo, Ivana Sullivan, Andrés Barba, Luís del Carpio, Agustí Barnadas, Ignasi Gich and Margarita Majem. Frontiers in Oncology. Publicat el setembre de 2020. Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune‑related adverse events in Advanced non‑small cell lung cancer patients receiving anti‑PD‑(L)1 blocking agents. Carlos Zamora, Mariona Riudavets, Georgia Anguera, Letícia Alserawan, Ivana Sullivan, Andrés Barba, Jorgina Serra, M. Angels Ortiz, Pablo Gallardo, Lidia Perea, Javier Gavira, Agustí Barnadas, Margarita Majem, Silvia Vidal. Cancer Immunol Immunother. Publicat 2 de gener de 2021. The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in advanced NSCLC patients treated with PD-(L)1 blockade agents. Carlos Zamora Atenza, Geòrgia Anguera, Mariona Riudavets Melià, Letícia Alserawan De Lamo, Ivana Sullivan, Andrés Barba Joaquin, Jorgina Serra Lopez, M. Angels Ortiz, Maria Mulet, Sílvia Vidal, Margarita Majem Tarruella. Anguera, G.; Mulet, M.; Zamora, C.; Osuna-Gómez, R.; Barba, A.; Sullivan, I.; Serra-López, J.; Cantó, E.; Vidal, S.; Majem, M. Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients. Biomedicines 2024, 12, 958. https://doi.org/10.3390/ biomedicines12050958 Alserawan, L.; Mulet, M.; Anguera, G.; Riudavets, M.; Zamora, C.; Osuna-Gómez, R.; Serra-López, J.; Barba Joaquín, A.; Sullivan, I.; Majem, M.; et al. Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors. Cancers 2024, 16, 1759. https://doi.org/10.3390/cancers16091759
MATERIAL CIENTÍFIC: - Fitxes educació sanitària per a esquemes de combinación de Checkpoint Inhibitors i altres tractaments. Serra-López, J, Soria-Verdugo A., Miranda A., López-Ortega, Zazo B., De Finis M., Rodríguez M, Román R.
- Guía per a infermeres sobre el maneig de pacients en tractament amb immunoteràpia. SEEO-SEOM. Novembre 2023. Serra-López, J, Soria-Verdugo A., Miranda A., López-Ortega, N, Majem M., Castaño. E.
- Guía per a pacients sobre la immunoteràpia. SEEO-SEOM. Juny 2022. Serra-López, J, Soria-Verdugo A., Miranda A., López-Ortega, N, Majem M., Castaño. E.
|
